Medications such as Ozempic (semaglutide), Wegovy, Mounjaro (tirzepatide) and Saxenda (liraglutide) have changed how obesity and insulin resistance are treated. For women with polycystic ovary syndrome, that shift has raised an obvious question. If these medications improve the metabolic problems that sit underneath PCOS, could they also improve fertility?
The question has been amplified by stories of unexpected pregnancies during treatment, and by the phrase "Ozempic babies" now circulating widely on social media. What the conversation about Ozempic and PCOS often loses is the difference between a medication that treats infertility directly and one that removes a barrier standing in its way. Those are not the same thing, and the distinction matters a great deal if you are trying to conceive.
Quick answer: Ozempic is not a fertility drug. In women with PCOS, it may improve fertility indirectly by supporting weight loss, improving insulin sensitivity, lowering androgen levels and helping ovulation return. Current guidance is to use contraception during treatment and stop the medication before trying to conceive.
Lifestyle matters for fertility. A BMC Public Health study found that women with 4–5 healthy habits had a 59% lower risk of infertility.
Fill out the questionnaire, and get a personalised, holistic and evidence-based programme tailored to you.
takes 3 minutes to completePCOS affects roughly 8 to 13% of women of reproductive age and is one of the leading causes of ovulatory infertility. It is a metabolic and hormonal condition as much as a reproductive one, which is why its effects reach well beyond the menstrual cycle.
Women with PCOS commonly experience irregular or absent ovulation, insulin resistance, weight gain or difficulty losing weight, elevated androgen levels, and irregular menstrual cycles. These disturbances interact with one another, and together they can make conception considerably harder. Understanding how PCOS is diagnosed is often the first step towards addressing them.
The encouraging part is that this pattern is not fixed. Improving insulin sensitivity and achieving even modest weight loss can often restore ovulation and improve fertility outcomes. This is the mechanism that makes the whole question worth taking seriously (ASRM).
GLP-1 receptor agonists were originally developed to treat type 2 diabetes. They reduce appetite, increase feelings of fullness, slow stomach emptying, improve insulin sensitivity and promote weight loss.
The medications most people are asking about are semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound) and liraglutide (Saxenda, Victoza). None of them is approved as a fertility treatment. What they may do is improve reproductive health indirectly in women whose fertility is being affected by metabolic dysfunction, which is a meaningfully narrower claim (ASRM).
Emerging research suggests GLP-1 medications may improve several of the factors that contribute to infertility in PCOS. Studies have reported improvements in weight, insulin resistance, menstrual regularity, ovulation frequency and androgen levels.
Those changes can increase the likelihood of spontaneous conception, particularly in women with obesity and insulin resistance. Recent studies have also reported higher ovulation rates and increased natural pregnancy rates among women with PCOS treated with semaglutide. The same effect can be pursued through balancing blood sugar without medication, which is why lifestyle work remains part of every guideline.
This content is for educational purposes only. It has been reviewed for scientific accuracy, but it does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding medical questions or fertility treatment decisions.
Reviewed for scientific accuracy by: Dr. Mona Bungum
Last reviewed: August 2026
Lifestyle matters for fertility. A BMC Public Health study found that women with 4–5 healthy habits had a 59% lower risk of infertility.
Fill out the questionnaire, and get a personalised, holistic and evidence-based programme tailored to you.
takes 3 minutes to completeWhat remains genuinely unclear is whether the benefit comes from the medication itself or from the weight loss and metabolic improvement that follow it. That distinction has not yet been resolved.
Evidence Grade: B (Moderate). Supported by clinical studies and systematic reviews, though long-term fertility data remain limited (ASRM).
Many women with PCOS ovulate irregularly and reasonably assume that pregnancy is unlikely in any given cycle. When insulin resistance improves and weight decreases, ovulation can resume without warning.
This is the mechanism behind most "Ozempic baby" stories. It is not evidence that the medication is a fertility drug. It is evidence that metabolic barriers were suppressing a reproductive system that was otherwise capable of working. For women in this position, tracking ovulation during treatment is more useful than assuming cycles will stay unpredictable, and many find they can conceive naturally with PCOS once ovulation returns.
Evidence Grade: B (Moderate). Based on observational studies and a growing body of real-world clinical experience (The Guardian).
This is one of the more important unanswered questions in reproductive medicine at present.
Weight loss before IVF may improve metabolic health and ovarian response in some women with obesity and PCOS. Current evidence does not, however, demonstrate that GLP-1 medications increase live birth rates after IVF. Several studies are underway evaluating whether pre-treatment with semaglutide or tirzepatide before a cycle changes outcomes, but the results are not yet in.
For now there is insufficient evidence to recommend GLP-1 medications specifically to improve IVF success. Women weighing up their options may find it more useful to look at the established fertility treatments for PCOS first.
Evidence Grade: C (Limited). Promising but insufficient data on pregnancy and live birth outcomes.
Current international guidelines recommend effective contraception while taking GLP-1 receptor agonists if pregnancy is possible. The reason is straightforward: human pregnancy safety data remain limited, and absence of evidence is not the same as evidence of safety.
Manufacturers advise discontinuing semaglutide at least two months before attempting conception, because the medication stays in the body for an extended period. Similar guidance applies to the other long-acting GLP-1 medications (Reuters).
In practice, many fertility specialists treat these medications as part of a pre-conception optimisation strategy rather than a conception strategy. The medication does its work first, treatment stops, and only then do conception attempts or fertility treatment begin. This sequencing is also worth understanding in the wider context of weight loss medications and fertility.
Evidence Grade: A (Strong). Supported by international PCOS guidelines and manufacturer recommendations (ASRM).
Because ovulation can return unexpectedly, some women discover a pregnancy while still taking the medication.
The current recommendation is to stop the medication and contact your healthcare provider. Reassuringly, emerging data suggest that accidental exposure during early pregnancy does not appear to be associated with a major increase in adverse pregnancy outcomes, although the available evidence is still limited (Reuters).
The practical message is not to panic. An unexpected pregnancy on a GLP-1 medication is a reason to speak to a clinician promptly, not a reason to assume harm has been done.
Evidence Grade: C (Limited). Human safety data are accumulating but remain incomplete.
The evidence points fairly consistently in one direction. The greatest potential benefit appears in women with PCOS and obesity, PCOS and insulin resistance, irregular ovulation, or persistent difficulty losing weight despite genuine lifestyle effort.
There is considerably less evidence supporting GLP-1 use in women with lean PCOS, a normal BMI, or unexplained infertility without metabolic dysfunction. If metabolic dysfunction is not the barrier, removing it is unlikely to be the answer. For these women, the more productive route is usually to improve fertility with PCOS through targeted changes rather than medication.
Evidence Grade: B (Moderate). Most published studies involve women with overweight, obesity and insulin resistance (ASRM).
If you are considering Ozempic or another GLP-1 medication and hope to become pregnant, a few principles are worth holding onto.
Discuss your fertility goals with your healthcare provider before starting treatment rather than after. Keep prioritising nutrition, physical activity, sleep and stress management, since these remain the foundation whether or not medication is involved, and evidence-based nutrition for PCOS works alongside treatment rather than being replaced by it. Some women also find that well-chosen supplements for PCOS support this groundwork.
Use effective contraception during treatment unless specifically advised otherwise, and plan to stop treatment before actively trying to conceive or starting fertility treatment. Above all, remember that restoring ovulation can increase fertility sooner than you expect. Baseline fertility testing before you start, and a conversation with one of the trusted clinics in your area, will give you a clearer picture of where you actually stand.
GLP-1 medications are not fertility drugs, and the honest framing is that they may improve fertility in women with PCOS by treating something else. Weight loss, better insulin sensitivity, lower androgen levels and returning ovulation are real changes with real reproductive consequences, but they are downstream effects of metabolic treatment rather than a direct fertility intervention. The strongest evidence sits squarely in metabolic health, not in conception rates.
That is not a disappointing conclusion. For a woman with PCOS and obesity whose ovulation has been suppressed for years, addressing the metabolic barrier is a genuine step forward, and it may be the step that makes everything else possible. The caution that comes with it is simply about sequencing. These medications belong in the preparation phase, not the conception phase, and they work best as one part of a wider approach that includes nutrition, movement, sleep and proper clinical guidance. Understood that way, Ozempic and PCOS is a story about creating a healthier starting point rather than a shortcut to pregnancy.
Common questions from women weighing up GLP-1 medication alongside plans to conceive.
Indirectly, yes, for some women. Ozempic is not approved as a fertility treatment, but by improving insulin sensitivity and supporting weight loss it can help restore ovulation in women with PCOS. If irregular ovulation was the barrier to conception, removing that barrier can improve your chances.
Current guidance says no. International guidelines recommend effective contraception while taking GLP-1 receptor agonists, and manufacturers advise stopping semaglutide at least two months before attempting conception. Human pregnancy safety data are still limited, which is why the precautionary approach applies.
At least two months for semaglutide, based on manufacturer guidance, because the medication clears the body slowly. Timelines for other long-acting GLP-1 medications are broadly similar. Your clinician may recommend longer depending on your dose, your cycle and your treatment plan.
GLP-1 medications do not act on the ovaries directly. They improve insulin sensitivity and support weight loss, and both of those changes can reduce the hormonal disruption that suppresses ovulation in PCOS. The result is that cycles often become more regular and ovulation more frequent.
The pregnancies are real, but the explanation is usually misunderstood. Women with PCOS who assumed conception was unlikely can begin ovulating again once their metabolic health improves. The medication did not create fertility. It removed something that was suppressing it.
Stop the medication and contact your healthcare provider promptly. Emerging data suggest accidental exposure in early pregnancy does not appear to carry a major increase in adverse outcomes, though evidence remains limited. This is a reason to seek advice quickly, not a reason to assume harm.
There is currently insufficient evidence to say so. Weight loss before IVF may improve ovarian response in some women with obesity, but no clear evidence shows GLP-1 medications increase live birth rates. Studies evaluating pre-IVF treatment with semaglutide and tirzepatide are ongoing.
The evidence is much weaker here. Most published studies involve women with overweight, obesity or insulin resistance. If metabolic dysfunction is not driving your PCOS, a medication that treats metabolic dysfunction is less likely to change your fertility outcomes.
The same principles apply across the GLP-1 class. Tirzepatide (Mounjaro) and semaglutide (Wegovy) share the mechanism, the general fertility considerations and the pre-conception caution. Discuss the specific timing and dosing with your clinician, as clearance periods can differ.
Many women with PCOS do see menstrual regularity improve as insulin resistance and weight decrease, though the extent varies. It is worth tracking your cycle during treatment rather than assuming it will stay unpredictable, since ovulation can return earlier than expected.
For most women, yes. Nutrition, physical activity, sleep and stress management remain the foundation of PCOS management, and modest weight loss alone can restore ovulation. Medication is generally considered when those changes have not produced sufficient improvement, and it works best alongside them rather than instead of them.
